CagriSema
Amylin analog (cagrilintide) plus GLP-1 agonist (semaglutide). Once weekly.
Catalog reviewed Sep 30, 2026. Feed checks and price reviews are dated separately below. How we verify. Not medical advice.
What to know about CagriSema
An ingredient can have several brands, formulations, and approved uses. Prices and trial findings belong to the specific product and dose shown.
- Mean weight change in the cited trial
- −22.7% (-22.7% at 68 wks · REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema))
REDEFINE-1 (Phase 3) · 2.4 mg / 2.4 mg weekly (CagriSema)
- Stopped treatment for adverse events
- 6% (6% vs 3.7% placebo · REDEFINE 1 (2.4/2.4 mg, obesity))
REDEFINE 1 (2.4/2.4 mg, obesity)
- FDA shortage report
- In development
Investigational. Not FDA-approved.
- Route & frequency
- Once weekly
Trial averages are not personal predictions. Weight-loss, A1c, and side-effect figures may come from different trials, doses, or populations; follow each source for its context.
Investigational uses
CagriSema (investigational)
Obesity; type 2 diabetes (investigational)
An investigational fixed combination of the long-acting amylin analog cagrilintide and semaglutide, pairing two complementary satiety pathways.
Dosing, warnings & contraindications
Choose the named product and route. These are submitted label records, which may differ from current approved prescribing information. The product links above lead to current prescribing information. Indexed text omits tables and images; always read the full source label.
No approved label (investigational)
CagriSema is investigational. See its registered studies below. Search DailyMed.
Side effects reported in the trial
Reported adverse events and treatment discontinuation from the cited trial. These figures do not predict an individual response.
Discontinued for side effects
6% (6% vs 3.7% placebo · REDEFINE 1 (2.4/2.4 mg, obesity))
Reported as 6% vs 3.7% placebo. The share of trial participants who stopped treatment because of adverse events. This does not measure all side effects or all reasons for stopping.
Had nausea
55% (Nausea in the drug arm · REDEFINE 1 (2.4/2.4 mg, obesity))
The share of participants who reported nausea in this trial. Severity and duration are not captured by this percentage.
GI events dominated (nausea 55%, constipation 31%, vomiting 26%), mostly transient and mild-to-moderate; despite high nausea, AE discontinuation stayed relatively low.
From REDEFINE 1 (2.4/2.4 mg, obesity). Tolerability figures come from each drug's own trial (different doses, durations, and populations), so compare them as a guide, not a head-to-head. Source.
Direct trial comparisons
Read the results for the exact products, doses, and participants studied.
- REDEFINE-4: CagriSema vs tirzepatide
Adults with obesity and at least one associated condition. 84 weeks. Sponsor announcement.
Clinical trials
29 of 31 registered studies indexed. Showing up to 12 records: posted results first, then late-phase trials. Registry counts are not a measure of evidence quality.